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Abstract
Background
PPM1D (Protein phosphatase magnesium-dependent 1δ) is known as a damage response
regulator, a part of the p53 negative feedback loop. Truncating mutations of PPM1D, result-
ing in overexpression, are frequently found in the blood of patients with breast or ovarian
cancer. To identify whether the PPM1D mutation predisposes patients to such cancers or if
it results from the cancer and therapy, somatic PPM1D mutations in association with previ-
ous cancer and chemotherapy need to be explored.
Methods
We performed next-generation sequencing (NGS) analysis of blood samples from patients
suspected to have hereditary cancer. We grouped the patients according to their diagnoses
and history of chemotherapy. For the patients with PPM1D mutations in blood, tumor tissue
specimens were examined for the PPM1D mutation using conventional sequencing.
Results
A total of 1,195 patients, including 719 patients with breast cancer and 240 with ovarian
cancer, were tested, and four (~0.3%) had the truncating mutation in PPM1D. All truncating
mutations were in exon 6, in mosaic form, with a mean allele fraction of 11.15%. While 395
out of the 1,195 patients had undergone chemotherapy, the four with the truncating mutation
had a history of cisplatin-based chemotherapy. No corresponding mutations were identified
in the tumor tissues.
Conclusions
We investigated the frequency of the somatic mosaic PPM1D mutation, in patients with
breast or ovarian cancer, which is suggested to be low and related to a history of cisplatin-
based chemotherapy. It may be a marker of previous exposure to selective pressure for
cells with an impaired DNA damage response.
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Introduction
Protein phosphatase magnesium-dependent 1δ (PPM1D) encodes the Wip1 phosphatase and
is known as a regulator of the DNA damage response pathway. Wip1 dephosphorylates the
tumor suppressor p53, CHK1, CHK2 and other key components of the pathway as part of a
negative feedback regulatory loop [1,2]. Induced by p53 initiating cell cycle arrest or apoptosis
upon cellular stress, Wip1 downregulates p53 level and drives the cell back to its normal state
[2].
Gain-of-function mutations of PPM1D have been reported in a wide variety of cancers,
including breast cancer and ovarian cancer [3–10]. Over suppression of p53 releases the cell
from arrest to proceed the cell cycle, resulting in carcinogenesis [11]. Although copy number
gain and increased expression level of PPM1D have been reported, [4,7,10], it has also been
reported that truncating mutations in exon 6 of PPM1D lead to its overexpression, escaping
from the control of degradation signaling [3,11]. In recent studies, these truncating mutations
of PPM1D in mosaic form were found in the blood with higher frequency among patients with
ovarian cancer or breast cancer than in the control group [5,12], suggesting a causal relation-
ship between the mutations and the cancers. In contrast, it has also been reported that PPM1D
mosaic truncating mutations in the blood have been associated with chemotherapy rather than
predisposition to the cancers [9,13].
To support this idea, the association of somatic PPM1D mutations with previous cancer
and chemotherapy needs to be explored. In this study, we investigated the prevalence and
characteristics of the truncating PPM1Dmutation among patients with cancer by using NGS
hereditary cancer panel testing. We analyzed the somatic truncating PPM1Dmutation status
in the context of previous chemotherapy.
Methods
Patients and samples
A total of 1,195 peripheral blood samples of patients suspected to have had hereditary cancer
according to National Comprehensive Cancer Network guideline (https://www.nccn.org/
professionals/physician_gls/pdf/genetics_screening.pdf, registration required) in Severance
Hospital between July 2016 and July 2018 were subjected to NGS gene panel testing for heredi-
tary cancer. For those patients, investigation of truncating mutations of PPM1D was per-
formed. For the three cases with identified PPM1D truncating mutations, corresponding
formalin-fixed paraffin-embedded primary cancer specimens were subjected to mutational
analysis. Written form of informed consent was obtained for all patients. The current study
was approved by Severance Hospital Institutional Review Board (4-2019-0021).
DNA extraction and sequencing
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit
(Qiagen, Venlo, The Netherlands). Approximately 500 ng of genomic DNA was fragmented
into segments between 150 and 250 bp long, using the Bioruptor Pico Sonication System
(Diagenode, Liège, Belgium), which were then end repaired and ligated to Illumina adapters
(Illumina, San Diego, CA, USA) and indices. Sequencing libraries were then hybridized with
the capture probes (Celemics, Seoul, Korea). All procedures were performed per the manu-
facturer’s instructions. Enriched DNA was then amplified, and clusters were generated and
sequenced on a NextSeq 550 instrument (Illumina) with 2×151 bp reads. NGS tests were
performed using a custom gene panel consisting of 65 genes related to hereditary cancer
(S1 Table). For genomic DNA extraction of tumor samples, Maxwell RSC DNA FFPE
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Kits (Promega, Madison, WI, USA) were used and Sanger sequencing of the specimen was
performed.
Data analysis and interpretation
Reads were aligned using the Burrows-Wheeler Alignment tool (0.7.12) on human genomic
reference sequences (GRCh37) [14]. To identify single nucleotide sequence variations, the
HaplotypeCaller in the Genome Analysis Toolkit package (3.8–0) was used [15]. All mutations
were annotated using ANNOVAR and VEP (87) software [16,17]. Detected variants were fur-
ther examined by visual verification using the Integrative Genomics Viewer [18]. The pathoge-
nicity of variants was classified according to the American College of Medical Genetics and
Genomics (ACMG) criteria [19].
Results
Sequencing data and patients
A total of 1,195 patients were enrolled. Among them, 725 patients had breast cancer (60.7%)
and 246 had ovarian cancer (20.6%), as summarized in Table 1. Three hundred and ninety five
patients out of 1,195 (33.1%) had received chemotherapy before genetic testing. The median
depth of coverage of the gene panel was 691× with a maximum depth of 7,976×. The median
depth of the PPM1D gene was 990x, ranging from 650x to 2,277x.
Truncating PPM1Dmutations
Truncating mutations in PPM1D were detected in four patients (~0.3% of total cases), one (1/
725, 0.14%) with breast cancer and three (3/246, 1.22%) with ovarian cancer (Table 2). All
truncating mutations were in mosaic form on the cluster region within a 370-base-pair region
in exon 6, the final exon of the gene [5]. The mean variant allele fraction (VAF) was 11.15%,
ranging from 5.4% to 15.4%. Meanwhile, 15 missense variants of PPM1D were identified in
each fifteen patient except the four harboring the truncating mutations in PPM1D. They were
located in exon 1, 2, 5, and 6 and variant allele frequencies were approximately 0.5 (S2 Table).
They were all variants with uncertain clinical significance according to the ACMG guideline.
The mean age at diagnosis of the PPM1D truncating mutation carriers was 63.5 years
(range, 52–82 years), and they did not have family history of breast or ovarian cancer. One
case (P2) had a concurrent truncating mutation in BRCA1 (c.2345T>A, p.Leu785Ter), which
Table 1. Cancer types of people who have undergone NGS gene panel testing for hereditary cancer.
Type of cancer n (%)
Breast 719 (60.2)
Ovarian 240 (20.1)
Breast and ovarian 6 (0.5)
Colorectal 134 (11.2)
Endometrial 15 (1.3)
Retinoblastoma 13 (1.1)
Pancreatic 12 (1.0)
Gastric 11 (0.9)
other 45 (3.8)
total 1195
Breast and/or ovarian cancer were the most common (80.6%)
https://doi.org/10.1371/journal.pone.0217521.t001
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is classified as a pathogenic variant according to the ACMG guideline, in addition to the trun-
cating PPM1D mutation. The cancer type was invasive ductal carcinoma in a case with breast
cancer and serous carcinoma in all cases with ovarian cancer (Table 2).
All four patients with a PPM1Dmutation had a history of chemotherapy (odds ratio, 18.4;
95% confidence interval, 0.990–342.67; p = 0.051). Chemotherapy regimens included cisplatin
or carboplatin for all four patients. The time interval between chemotherapy and the NGS test
ranged from 10 months to 20 years.
PPM1Dmutation status in cancer specimen
We obtained the peripheral blood and tumor tissues of three mutation-positive cases (P1, P2
and P4) except for P3 whose specimen was not available. and performed conventional PCR
and sequencing. All the low level PPM1Dmutations in blood samples were identified by con-
ventional sequencing, but no corresponding mutations in the tumor tissues were observed, as
suggested in the previous reports [5,12] (S1 Fig).
Discussion
PPM1D is known as a DNA damage response regulator, which is a part of the p53 regulatory
feedback loop. PPM1D is induced by activated p53, and it dephosphorylates and inactivates
p53 as well as other target proteins involved in DNA repair [20,21]. It negatively regulates the
p53-mediated apoptosis and returns the cell to its original state [22].
Increased expression of PPM1D and p53 over suppression have been reported in various
cancer tissues [4,7,10]. Notably, PPM1D truncating mutations are invariably found in exon 6
and are known to enhance its function [3,11]. This results in mRNA without the last exon,
which is responsible for the degradation signal, making the molecule more stable. This leads to
a gain of function effect by more strongly dephosphorylating its targets compared to the wild
type dose [11,23]. Because PPM1D also dephosphorylates and inactivates other proteins work-
ing in the DNA damage repair system, the truncating mutations of PPM1D are assumed to
have a role in carcinogenesis in various types of cancers.
Somatic mosaic mutations of PPM1D in the blood have been more frequently found in
patients with various cancers including breast and ovarian cancers compared to control
groups, raising concern that it has a possible role in cancer predisposition [5,9,12]. It is
assumed that the cancer driver mutation is enriched in tumor tissue compared to other tissues
such as blood; however, no corresponding mutations have been identified in tumor tissues in
most cases [5,12].
In 2016, Pharoah et al. and Swisher et al. suggested that somatic mosaic mutations in
PPM1D in the blood resulted from previous chemotherapy [13,24]. Platinum-based chemo-
therapy such as cisplatin is the basis of the chemotherapy regimen for ovarian and breast
cancers. Cisplatin, in particular, is known to cross-link with DNA and cause DNA sequence
changes at a high frequency [25]. The fact that most of the somatic mosaic mutations in
PPM1D were observed in the blood of patients with ovarian and breast cancer supports the
association of these mutations with platinum-based chemotherapy [13,24,26].
Our NGS hereditary cancer panel analysis with blood revealed somatic mosaic mutations of
PPM1D in four out of 965 patients with breast and/or ovarian cancer (0.41%). The frequency
was similar to that reported previously (0.32% in breast and/or ovarian cancer), and the muta-
tions were also within the reported clustering region of exon 6, with no particular hotspots
[5]. However, the percentage of individuals harboring the mutation among patients with lym-
phoid malignancy and prior chemotherapy was reported as high as 20% using more sensitive
method, error-corrected sequencing [27]. Along with previous reports, the mutations present
Somatic mosaic PPM1D mutations
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in low fractions in blood were not enriched or identified in the tumor tissues examined.
Moreover, a patient had a concurrent pathogenic BRCA1mutation, which predisposes more
strongly to the condition. These results could be supportive of mosaic PPM1Dmutations
resulting from treatment rather than causing a predisposition to breast or ovarian cancer.
There were 395 patients who underwent previous chemotherapy, and all four patients with the
PPM1Dmutation received cisplatin-based chemotherapy (p = 0.051). Those four patients had
undergone chemotherapy from 10 months to 20 years ago. Concluding that the PPM1Dmuta-
tion predisposed patients to breast or ovarian cancer requires more evidence. In this context,
somatic PPM1Dmutations could be a result of expansion of a PPM1D-mutated clone under
selective pressure by cisplatin chemotherapy, rather than a risk factor or cause of the respective
cancers.
Indeed, somatic mosaic mutations of PPM1D have been reported in populations with clonal
hematopoiesis of indeterminate potential (CHIP) [28,29]. In our study, the median age of the
patients with PPM1D truncating variants was 60 (range, 52–82), which was a little higher than
the age of patients with familial breast and ovarian cancer. Rather, clonal mosaic hematopoie-
sis could be common in this age group. PPM1Dmutations are far from being common in the
general population and their frequency is increasing in association with prior chemotherapy
[28–30]. It was the most common mutation associated with CHIP in patients with cisplatin-
based myeloablative therapy or therapy-related myeloid neoplasm (TMN) [26,30]. This is
because the pre-existing or therapy-induced PPM1Dmutated clones have survival advantages
in the context of cisplatin therapy, resisting apoptosis and thus chemotherapy [26,31]. Consid-
ering the recent studies stating the association between the clonal PPM1Dmutations in blood
and TMN, the mutations could be associated with an increased risk for certain subtypes of
hematologic malignancy [26,30]. According to the recent study, patients with CHIP showed
a higher incidence of TMN and shorter overall survival among patients with myeloablative
therapy [30]. Among them, patients bearing PPM1D as CHIP showed significantly poorer out-
comes [30]. For better precision in treatment, the increased risk of such hematologic malig-
nancy should be taken into account in long-term follow up.
Conclusions
In conclusion, we investigated somatic mosaic PPM1D mutations in patients with various
cancers, including breast and ovarian cancers and found that all four patients bearing the
truncating mutations had a history of cisplatin-based chemotherapy. This suggests that these
mutations may be due to the increase of a mutant clone under selective pressure by cytotoxic
therapy.
Supporting information
S1 Fig. Confirmation of truncating mutations in blood and cancer specimens by Sanger
sequencing. Samples from three (P1, P2 and P4) who had a low percentage of truncating
mutations in peripheral blood by NGS were confirmed by Sanger sequencing. However, no
corresponding mutations in primary tumor tissues were observed.
(TIF)
S1 Table. Genes included in the custom NGS gene panel.
(DOCX)
S2 Table. Characteristics of PPM1Dmissense mutation carriers.
(DOCX)
Somatic mosaic PPM1D mutations
PLOS ONE | https://doi.org/10.1371/journal.pone.0217521 June 26, 2019 6 / 8
Author Contributions
Conceptualization: Borahm Kim, Seung-Tae Lee.
Data curation: Borahm Kim, Dongju Won.
Formal analysis: Borahm Kim, Dongju Won.
Supervision: Seung-Tae Lee, Jong Rak Choi.
Writing – original draft: Borahm Kim, Dongju Won.
Writing – review & editing: Seung-Tae Lee, Jong Rak Choi.
References
1. Oliva-Trastoy M, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann C, et al. The Wip1
phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene.
2007; 26: 1449–1458. https://doi.org/10.1038/sj.onc.1209927 PMID: 16936775
2. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 Phosphatase acts as a gate-
keeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007; 12: 342–354. https://doi.org/10.1016/j.
ccr.2007.08.033 PMID: 17936559
3. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, et al. Exome sequencing identifies somatic gain-
of-function PPM1D mutations in brainstem gliomas. Nat Genet. 2014; 46: 726–730. https://doi.org/10.
1038/ng.2995 PMID: 24880341
4. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, et al. Medulloblastomas overex-
press the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008; 86: 245–256. https://doi.org/
10.1007/s11060-007-9470-8 PMID: 17932621
5. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D mutations are
associated with predisposition to breast and ovarian cancer. Nature. 2013; 493: 406–410. https://doi.
org/10.1038/nature11725 PMID: 23242139
6. Liu S, Qi L, Han W, Wan X, Jiang S, Li Y, et al. Overexpression of wip1 is associated with biologic
behavior in human clear cell renal cell carcinoma. PLoS One. 2014; 9: e110218. https://doi.org/10.
1371/journal.pone.0110218 PMID: 25334029
7. Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, et al. PPM1D gene ampli-
fication and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
Mod Pathol. 2010; 23: 1334–1345. https://doi.org/10.1038/modpathol.2010.121 PMID: 20543821
8. Peng TS, He YH, Nie T, Hu XD, Lu HY, Yi J, et al. PPM1D is a prognostic marker and therapeutic target
in colorectal cancer. Exp Ther Med. 2014; 8: 430–434. https://doi.org/10.3892/etm.2014.1762 PMID:
25009596
9. Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwinski R, Rusin M. Truncating mutations of PPM1D
are found in blood DNA samples of lung cancer patients. Br J Cancer. 2015; 112: 1114–1120. https://
doi.org/10.1038/bjc.2015.79 PMID: 25742468
10. Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, et al. WIP1 phospha-
tase as a potential therapeutic target in neuroblastoma. PLoS One. 2015; 10: e0115635. https://doi.org/
10.1371/journal.pone.0115635 PMID: 25658463
11. Kleiblova P, Shaltiel IA, Benada J, Sevcik J, Pechackova S, Pohlreich P, et al. Gain-of-function muta-
tions of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol. 2013; 201: 511–521.
https://doi.org/10.1083/jcb.201210031 PMID: 23649806
12. Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, et al. PPM1D mutations in circulat-
ing white blood cells and the risk for ovarian cancer. J Natl Cancer Inst. 2014; 106: djt323. https://doi.
org/10.1093/jnci/djt323 PMID: 24262437
13. Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, et al. PPM1D Mosaic Trun-
cating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer
Inst. 2016; 108. https://doi.org/10.1093/jnci/djv347 PMID: 26823519
14. Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinfor-
matics. 2014; 30: 2843–2851. https://doi.org/10.1093/bioinformatics/btu356 PMID: 24974202
15. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation dis-
covery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43: 491–498.
https://doi.org/10.1038/ng.806 PMID: 21478889
Somatic mosaic PPM1D mutations
PLOS ONE | https://doi.org/10.1371/journal.pone.0217521 June 26, 2019 7 / 8
16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-through-
put sequencing data. Nucleic Acids Res. 2010; 38: e164. https://doi.org/10.1093/nar/gkq603 PMID:
20601685
17. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of geno-
mic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26: 2069–2070.
https://doi.org/10.1093/bioinformatics/btq330 PMID: 20562413
18. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative geno-
mics viewer. Nat Biotechnol. 2011; 29: 24–26. https://doi.org/10.1038/nbt.1754 PMID: 21221095
19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the inter-
pretation of sequence variants: a joint consensus recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405–424.
https://doi.org/10.1038/gim.2015.30 PMID: 25741868
20. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1:
an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis
Rev. 2008; 27: 123–135. https://doi.org/10.1007/s10555-008-9127-x PMID: 18265945
21. Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC, et al. Genetic variants and
mutations of PPM1D control the response to DNA damage. Cell Cycle. 2013; 12: 2656–2664. https://
doi.org/10.4161/cc.25694 PMID: 23907125
22. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, et al. p53-inducible wip1 phos-
phatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radia-
tion. Embo j. 2000; 19: 6517–6526. https://doi.org/10.1093/emboj/19.23.6517 PMID: 11101524
23. Macurek L, Benada J, Mullers E, Halim VA, Krejcikova K, Burdova K, et al. Downregulation of Wip1
phosphatase modulates the cellular threshold of DNA damage signaling in mitosis. Cell Cycle. 2013;
12: 251–262. https://doi.org/10.4161/cc.23057 PMID: 23255129
24. Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, et al. Somatic Mosaic Mutations in
PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2016; 2: 370–372.
https://doi.org/10.1001/jamaoncol.2015.6053 PMID: 26847329
25. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharma-
col. 2014; 740: 364–378. https://doi.org/10.1016/j.ejphar.2014.07.025 PMID: 25058905
26. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D Mutations Drive Clonal
Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018; 23: 700–713 e706.
https://doi.org/10.1016/j.stem.2018.10.004 PMID: 30388424
27. Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, et al. Cellular stressors contribute to
the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018; 9: 455.
https://doi.org/10.1038/s41467-018-02858-0 PMID: 29386642
28. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoie-
sis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371: 2477–2487.
https://doi.org/10.1056/NEJMoa1409405 PMID: 25426838
29. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated
with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20: 1472–1478. https://doi.org/
10.1038/nm.3733 PMID: 25326804
30. Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal Hematopoiesis Asso-
ciated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin
Oncol. 2017; 35: 1598–1605. https://doi.org/10.1200/JCO.2016.71.6712 PMID: 28068180
31. Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, et al. PPM1D truncating mutations confer
resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018:
blood-2018-2005-850339. https://doi.org/10.1182/blood-2018-05-850339 PMID: 29954749
Somatic mosaic PPM1D mutations
PLOS ONE | https://doi.org/10.1371/journal.pone.0217521 June 26, 2019 8 / 8
